Rheonix | GenomeWeb

Rheonix

Rheonix has won an administrative supplement to an existing SBIR grant to develop the Zika test using its CARD cartridge and Encompass Optimum platform.

The firm's dual assay for host antigen to HIV as well as viral RNA was described in a proof-of-principle study earlier this year. 

Rheonix Raises $28.6M

The Ithaca, New York-based firm will use the financing to ramp up commercialization of its molecular diagnostic testing platforms.

The firm is aiming at in vitro diagnostics, applied markets, and next-generation sequencing sample preparation.

The Phase II grant will provide the company with funding to develop a commercial-ready version of the test.

The fully automated self-confirming assay will simultaneously detect HIV/AIDS antibodies and viral RNA in a single specimen.

HandyLab has been awarded

NEW YORK (GenomeWeb) – Rheonix will soon begin a clinical trial for a microarray-based test for sexually transmitted infections with the aim of submitting the assay to the US Food and Drug Administration for clearance next year.

Lawrence Livermore National Security has been awarded

NEW YORK (GenomeWeb) – Rheonix today said it received a Small Business Innovation Research Phase I Fast-Track grant to complete the development of its fully automated self-confirming assay for the simultaneous detection of HIV/AIDS antibodies and viral RNA in a single specimen.

Pages

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.